@article{4f150f78b6944c53835d34615f640d53,
title = "Collagen remodeling in the hypoxic tumor- mesothelial niche promotes ovarian cancer metastasis",
abstract = "Peritoneal metastases are the leading cause of morbidity and mortality in high-grade serous ovarian cancer (HGSOC). Accumulating evidence suggests that mesothelial cells are an important component of the metastatic microenvironment in HGSOC. However, the mechanisms by which mesothelial cells promote metastasis are unclear. Here, we report that the HGSOC tumor-mesothelial niche was hypoxic, and hypoxic signaling enhanced collagen I deposition by mesothelial cells. Specifically, hypoxic signaling increased expression of lysyl oxidase (LOX) in mesothelial and ovarian cancer cells to promote collagen crosslinking and tumor cell invasion. The mesothelial niche was enriched with fibrillar collagen in human and murine omental metastases. Pharmacologic inhibition of LOX reduced tumor burden and collagen remodeling in murine omental metastases. These findings highlight an important role for hypoxia and mesothelial cells in the modification of the extracellular matrix and tumor invasion in HGSOC. Significance: This study identifies HIF/LOX signaling as a potential therapeutic target to inhibit collagen remodeling and tumor progression in HGSOC.",
author = "Suchitra Natarajan and Foreman, {Kaitlyn M.} and Soriano, {Michaela I.} and Rossen, {Ninna S.} and Hussein Shehade and Fregoso, {Daniel R.} and Eggold, {Joshua T.} and Venkatesh Krishnan and Oliver Dorigo and Krieg, {Adam J.} and Heilshorn, {Sarah C.} and Subarna Sinha and Fuh, {Katherine C.} and Rankin, {Erinn B.}",
note = "Funding Information: We would like to thank Mr. Jonathan Mulholland and Dr. David Castaneda-Castellanos for assistance with SHG imaging. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense Ovarian Cancer Research Program under award no. W81XWH-15-1-0097, the Mary Kay Ash Charitable Foundation, the Rivkin Center for Ovarian Cancer, and the My Blue Dots fund (all to E.B. Rankin). Funding Information: This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense Ovarian Cancer Research Program under award no. W81XWH-15-1-0097, the Mary Kay Ash Charitable Foundation, the Rivkin Center for Ovarian Cancer, and the My Blue Dots fund (all to E.B. Rankin). Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",
year = "2019",
doi = "10.1158/0008-5472.CAN-18-2616",
language = "English",
volume = "79",
pages = "2271--2284",
journal = "Cancer research",
issn = "0008-5472",
number = "9",
}